No correlation between <i>WT1</i> SNP genotypes and <i>WT1</i> RNA expression in ccRCC.

<p><i>WT1</i>, Wilms’ tumour gene 1; −, homozygous minor allele was not identified in tumour-free tissues.</p

Characteristics of Wilms’ tumour gene 1 (<i>WT1</i>) single nucleotide polymorphism (SNP) in ccRCC tumour and corresponding tumour-free renal cortical tissues.

<p>SNP, single nucleotide polymorphism; HWE, Hardy-Weinberg equilibrium.</p

No correlation between <i>WT1</i> SNP genotypes and clinical and pathologic characteristics in patients with ccRCC.

<p>DSS, disease specific survival; OS, overall survival;</p><p><i>p</i>*, significance compared between patients with <i>WT1</i> SNP homozygous or heterozygous for the minor allele versus wild-type.</p

Chromatogram showing the nucleotide sequence with the novel heterozygous missense mutation 536 C→A in <i>WT1</i>.

<p>Chromatogram showing the nucleotide sequence with the novel heterozygous missense mutation 536 C→A in <i>WT1</i>.</p

Prognostic impact of Wilms’ tumour gene 1 (<i>WT1</i>) single nucleotide polymorphism (SNP) rs16754 in ccRCC.

<p>(A) Overall Survival (OS) for patients with rs16754 wild-type, heterozygous and homozygous minor allele and (B) Disease-specific survival (DSS) for patients with rs16754 wild-type, heterozygous and homozygous minor allele.</p

Prognostic impact of Wilms’ tumour gene 1 (<i>WT1</i>) single nucleotide polymorphisms (SNPs) in exon 1 in ccRCC.

<p>(A) Overall Survival (OS) for patients with wild-type, heterozygous and homozygous minor allele in exon 1 and (B) Disease-specific survival (DSS) for patients with wild-type, heterozygous and homozygous minor allele in exon 1.</p

Survival analysis of Wilms’ tumour gene 1 (<i>WT1</i>) single nucleotide polymorphism (SNP) in ccRCC based on genotypes.

<p>(A) Kaplan-Meier curves of Overall Survival (OS) for patients with SNP genotypes in <i>WT1</i> and (B) Disease-specific survival (DSS) for patients with <i>WT1</i> SNP genotype.</p